Navigation Links
Soy isoflavone may inhibit common gastrointestinal illness in infants
Date:9/6/2007

The soy isoflavone genistin--at concentrations present in soy infant formula-- may reduce a babys susceptibility to rotavirus infections by as much as 74 percent, according to a University of Illinois study published in Septembers Journal of Nutrition.

Rotavirus is the primary cause of diarrhea in infants, affecting virtually all children before age five. In the United States, it mainly leads to dehydration, doctors visits, and parents missing work to care for sick children. In developing countries, though, rotavirus causes approximately 611,000 deaths each year, said Sharon Donovan, the Melissa M. Noel Professor of Nutrition at the U of I.

Although rotavirus vaccines have recently become available, they are expensive and cannot be given to some infants, she said.

Its exciting to think that the isoflavones in soy formula could be a cost-effective nutritional approach to decreasing the incidence and severity of rotavirus infections, especially among children in developing countries who are most at risk, said the scientist of her work with doctoral candidate Aline Andres, who conducted the experiments.

In the study, cells in culture were exposed to rotavirus in the absence or presence of soy isoflavones, biologically active compounds in soy that are thought to have health benefits. Soy contains a number of different forms of isoflavones, and all were tested individually and as the complete mixture present in infant formula.

Genistin and the mixture significantly reduced rotavirus infectivity by 33 to 74 percent, she said. But when genistin was taken out of the mixture, anti-rotavirus activity was lost, suggesting that it is the active component in reducing infectivity.

Donovan focused her investigation on the isoflavone concentrations present in soy formula. That was the concentration at which rotavirus inhibition began to occur and then leveled off, indicating that theres an effective range, and beyond that, there is no additional inhibition or toxicity.

We then exposed the cells to different concentrations of rotavirus. If an infant had a severe infection or was exposed to a lot of rotavirus, we wondered if the isoflavones would still be as effective, she said.

The inhibition held up across a 16-fold range of rotavirus exposure. Even at the highest concentration of rotavirus particles, genistin or the mix of isoflavones inhibited infectivity, said Donovan.

Genistin appeared to diminish infectivity by inhibiting binding of the virus to tissue-culture cells, she said.

Donovans laboratory soon plans to begin studies with neonatal piglets, an excellent model for studying rotavirus infection and the nutritional effects of various components on the intestine.

Well be interested to see if we have the same results when we work with young animals, she said.


'/>"/>

Contact: Phyllis Picklesimer
p-pickle@uiuc.edu
217-244-2827
University of Illinois at Urbana-Champaign
Source:Eurekalert

Related biology news :

1. New research: Soy germ isoflavones reduce bone loss
2. Topical treatment shown to inhibit HIV and herpes simplex virus infection
3. Novel antiviral technology inhibits RSV infection in mice
4. HIV Patients May Be at Risk of Heart Problems When Taking Protease Inhibitor Drugs
5. Breast Cancer May Be Uniquely Sensitive To Inhibitors Of PI3K Pathway
6. Novel gene-silencing nanoparticles shown to inhibit Ewings sarcoma
7. Scientists inhibit cancer gene
8. Anthrax inhibitors identified by Burnham team
9. Researchers find molecule that inhibits regrowth of spinal nerve cells
10. Protease inhibitors reach beyond HIV
11. Techniques available to detect soil that inhibits destructive soybean pest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017 MedNet ... that supports the entire spectrum of clinical research, ... another record-breaking year for the organization in terms ... in MedNet,s eClinical products and services. The company,s ... marketplace success of iMedNet ...
(Date:1/12/2017)... 12, 2017  Trovagene, Inc. (NASDAQ: TROV ... today announced that it has signed agreements with seven ... the Middle East for commercialization ... the first wave of international distribution agreements for Trovagene,s ... samples. The initial partners will introduce Trovagene,s ...
(Date:1/12/2017)... and PUNE, India , January 12, 2017 ... Opportunities and Forecasts, 2015 - 2022," projects that the global biometric technology market is ... 19.4% from 2016 to 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... , Jan. 17, 2017  An international ... of Medicine and St. Boniface Hospital Albrechtsen Research ... peripheral neuropathy, an unmet health need affecting nearly ... Journal of Clinical Investigation, their results identify small ... prevent and reverse neuronal injury in animal models ...
(Date:1/17/2017)... LEXINGTON, Mass. , Jan. 17, 2017   ... clinical stage biopharmaceutical company developing innovative inhaled therapies to ... candidate for treating fungal infections in the lungs of ... Infectious Disease Product" (QIDP) by the U.S. Food & ... , which is designed to speed the development of ...
(Date:1/17/2017)... 17, 2017  Only nine percent of U.S. consumers ... while only 16 percent believe health insurance companies do, ... 36 percent of U.S. adults believe health care providers ... compared to hospitals (23%). "We are in ... Wendy Salomon , vice president of reputation management and ...
(Date:1/17/2017)... ... January 17, 2017 , ... Pono Ola , a mind-body wellness firm ... today the official launch of its much-anticipated Pono Board: a re-invented fitness and anti-fatigue ... development for over a year, the patented Pono Board is the world’s only exercise ...
Breaking Biology Technology: